Table 1.
Clinical and biological features of 104 AML patients
| N (%) | |
|---|---|
| Median age (range) | 59 (18–75) |
| Sex (male) | 59 (57) |
| Median WBC count/μL (range) | 9715 (400–218,700) |
| Unfavorable cytogeneticb | 44 (43) |
| ELN risk categorya | |
| Favorable | 37 (36) |
| Intermediate‐1 | 30 (29) |
| Intermediate‐2 | 17 (16) |
| High‐risk | 20 (19) |
| LAIP at diagnosis | 80 (77) |
| BM‐WT1 available at diagnosisb | 92 (88) |
| PB‐WT available at diagnosisb | 70 (67) |
| FLT3 ITD mutation | 22 (21) |
| FLT3 TKD mutation | 10 (10) |
| NPM1 mutation (on 99 patients) | 42 (42) |
| NPM1/FLT3ITD mutations (on 100 patients) | 14 (14) |
| Patients addressed to consolidation | 93 (83) |
| Patients addressed to intensification | 80 (77) |
| Patients addressed to allo‐SCT | 33 (32) |